U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Unresectable Pleural Epithelioid Mesothelioma

MedGen UID:
1749247
•Concept ID:
C5420307
•
Neoplastic Process

Definition

Pleural epithelioid mesothelioma that is not amenable to surgical resection. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVUnresectable Pleural Epithelioid Mesothelioma

Professional guidelines

PubMed

Meta-Analysis on the Combination of Chemotherapy With Programmed Death-Ligand 1 and Programmed Cell Death Protein 1 Blockade as First-Line Treatment for Unresectable Pleural Mesothelioma.
Tagliamento M, Di Maio M, Remon J, Bironzo P, Genova C, Facchinetti F, Aldea M, Le Péchoux C, Novello S, Barlesi F, Besse B, Planchard D
J Thorac Oncol 2024 Jan;19(1):166-172. Epub 2023 Aug 9 doi: 10.1016/j.jtho.2023.08.004. PMID: 37567387
FDA Approval Summary: Nivolumab in Combination with Ipilimumab for the Treatment of Unresectable Malignant Pleural Mesothelioma.
Nakajima EC, Vellanki PJ, Larkins E, Chatterjee S, Mishra-Kalyani PS, Bi Y, Qosa H, Liu J, Zhao H, Biable M, Hotaki LT, Shen YL, Pazdur R, Beaver JA, Singh H, Donoghue M
Clin Cancer Res 2022 Feb 1;28(3):446-451. Epub 2021 Aug 30 doi: 10.1158/1078-0432.CCR-21-1466. PMID: 34462287Free PMC Article
Irinotecan and Gemcitabine as Second-Line Treatment in Patients with Malignant Pleural Mesothelioma following Platinum plus Pemetrexed Chemotherapy: A Retrospective Study.
Koda Y, Kuribayashi K, Doi H, Kitajima K, Nakajima Y, Ishigaki H, Nakamura A, Minami T, Takahashi R, Yokoi T, Kijima T
Oncology 2021;99(3):161-168. Epub 2020 Oct 14 doi: 10.1159/000510691. PMID: 33053560

Recent clinical studies

Etiology

Brief Report: Real-World Toxicity and Survival of Combination Immunotherapy in Pleural Mesothelioma-RIOMeso.
McNamee N, Harvey C, Gray L, Khoo T, Lingam L, Zhang B, Nindra U, Yip PY, Pal A, Clay T, Arulananda S, Itchins M, Pavlakis N, Kao S, Bowyer S, Chin V, Warburton L, Pires da Silva I, John T, Solomon B, Alexander M, Nagrial A
J Thorac Oncol 2024 Apr;19(4):636-642. Epub 2023 Nov 28 doi: 10.1016/j.jtho.2023.11.014. PMID: 38036250
First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis.
Yang L, Song X, Zeng W, Zheng Z, Lin W
Orphanet J Rare Dis 2023 Oct 16;18(1):326. doi: 10.1186/s13023-023-02925-w. PMID: 37845696Free PMC Article
JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma.
Miyamoto Y, Kozuki T, Aoe K, Wada S, Harada D, Yoshida M, Sakurai J, Hotta K, Fujimoto N
J Immunother Cancer 2021 Oct;9(10) doi: 10.1136/jitc-2021-003288. PMID: 34711664Free PMC Article
Contemporary Analysis of Prognostic Factors in Patients with Unresectable Malignant Pleural Mesothelioma.
Billé A, Krug LM, Woo KM, Rusch VW, Zauderer MG
J Thorac Oncol 2016 Feb;11(2):249-55. Epub 2015 Dec 10 doi: 10.1016/j.jtho.2015.10.003. PMID: 26845118Free PMC Article
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Rivière F, Janicot H, Gervais R, Locher C, Milleron B, Tran Q, Lebitasy MP, Morin F, Creveuil C, Parienti JJ, Scherpereel A; French Cooperative Thoracic Intergroup (IFCT)
Lancet 2016 Apr 2;387(10026):1405-1414. Epub 2015 Dec 21 doi: 10.1016/S0140-6736(15)01238-6. PMID: 26719230

Diagnosis

Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into standard-of-care first-line treatment for patients with epithelioid malignant pleural mesothelioma-Protocol of the Immuno-MESODEC study.
Van den Bossche J, De Laere M, Deschepper K, Germonpré P, Valcke Y, Lamont J, Stein B, Van Camp K, Germonpré C, Nijs G, Roelant E, Anguille S, Lion E, Berneman Z
PLoS One 2024;19(7):e0307204. Epub 2024 Jul 15 doi: 10.1371/journal.pone.0307204. PMID: 39008481Free PMC Article
First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis.
Yang L, Song X, Zeng W, Zheng Z, Lin W
Orphanet J Rare Dis 2023 Oct 16;18(1):326. doi: 10.1186/s13023-023-02925-w. PMID: 37845696Free PMC Article
Cost Effectiveness and Budget Impact of Nivolumab Plus Ipilimumab Versus Platinum Plus Pemetrexed (with and Without Bevacizumab) in Patients with Unresectable Malignant Pleural Mesothelioma in Switzerland.
Barbier MC, Fengler A, Pardo E, Bhadhuri A, Meier N, Gautschi O
Pharmacoeconomics 2023 Dec;41(12):1641-1655. Epub 2023 Aug 12 doi: 10.1007/s40273-023-01305-3. PMID: 37572261Free PMC Article
Irinotecan and Gemcitabine as Second-Line Treatment in Patients with Malignant Pleural Mesothelioma following Platinum plus Pemetrexed Chemotherapy: A Retrospective Study.
Koda Y, Kuribayashi K, Doi H, Kitajima K, Nakajima Y, Ishigaki H, Nakamura A, Minami T, Takahashi R, Yokoi T, Kijima T
Oncology 2021;99(3):161-168. Epub 2020 Oct 14 doi: 10.1159/000510691. PMID: 33053560
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Rivière F, Janicot H, Gervais R, Locher C, Milleron B, Tran Q, Lebitasy MP, Morin F, Creveuil C, Parienti JJ, Scherpereel A; French Cooperative Thoracic Intergroup (IFCT)
Lancet 2016 Apr 2;387(10026):1405-1414. Epub 2015 Dec 21 doi: 10.1016/S0140-6736(15)01238-6. PMID: 26719230

Therapy

Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into standard-of-care first-line treatment for patients with epithelioid malignant pleural mesothelioma-Protocol of the Immuno-MESODEC study.
Van den Bossche J, De Laere M, Deschepper K, Germonpré P, Valcke Y, Lamont J, Stein B, Van Camp K, Germonpré C, Nijs G, Roelant E, Anguille S, Lion E, Berneman Z
PLoS One 2024;19(7):e0307204. Epub 2024 Jul 15 doi: 10.1371/journal.pone.0307204. PMID: 39008481Free PMC Article
What's Current and What's New in Mesothelioma?
Leal JL, Hoang W, Xue J, Dunne B, John T, Harden S
Clin Oncol (R Coll Radiol) 2022 Nov;34(11):771-780. Epub 2022 Sep 22 doi: 10.1016/j.clon.2022.08.029. PMID: 36155156
Chemotherapy With or Without Bevacizumab Should Be the Standard of Care for First-Line Unresectable Epithelioid Mesothelioma.
Fennell DA, Dulloo S
J Thorac Oncol 2022 Jan;17(1):34-37. doi: 10.1016/j.jtho.2021.08.004. PMID: 34930610
Immune Checkpoint Inhibition for Unresectable Malignant Pleural Mesothelioma.
Cui W, Popat S
Drugs 2021 Jun;81(9):971-984. Epub 2021 Jun 9 doi: 10.1007/s40265-021-01506-0. PMID: 34106454
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Rivière F, Janicot H, Gervais R, Locher C, Milleron B, Tran Q, Lebitasy MP, Morin F, Creveuil C, Parienti JJ, Scherpereel A; French Cooperative Thoracic Intergroup (IFCT)
Lancet 2016 Apr 2;387(10026):1405-1414. Epub 2015 Dec 21 doi: 10.1016/S0140-6736(15)01238-6. PMID: 26719230

Prognosis

Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into standard-of-care first-line treatment for patients with epithelioid malignant pleural mesothelioma-Protocol of the Immuno-MESODEC study.
Van den Bossche J, De Laere M, Deschepper K, Germonpré P, Valcke Y, Lamont J, Stein B, Van Camp K, Germonpré C, Nijs G, Roelant E, Anguille S, Lion E, Berneman Z
PLoS One 2024;19(7):e0307204. Epub 2024 Jul 15 doi: 10.1371/journal.pone.0307204. PMID: 39008481Free PMC Article
What's Current and What's New in Mesothelioma?
Leal JL, Hoang W, Xue J, Dunne B, John T, Harden S
Clin Oncol (R Coll Radiol) 2022 Nov;34(11):771-780. Epub 2022 Sep 22 doi: 10.1016/j.clon.2022.08.029. PMID: 36155156
Nivolumab plus ipilimumab in malignant pleural mesothelioma.
Travert C, Tomasini P, Greillier L
Expert Rev Anticancer Ther 2022 Aug;22(8):815-822. Epub 2022 Jul 25 doi: 10.1080/14737140.2022.2102482. PMID: 35835722
Immune Checkpoint Inhibition for Unresectable Malignant Pleural Mesothelioma.
Cui W, Popat S
Drugs 2021 Jun;81(9):971-984. Epub 2021 Jun 9 doi: 10.1007/s40265-021-01506-0. PMID: 34106454
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Rivière F, Janicot H, Gervais R, Locher C, Milleron B, Tran Q, Lebitasy MP, Morin F, Creveuil C, Parienti JJ, Scherpereel A; French Cooperative Thoracic Intergroup (IFCT)
Lancet 2016 Apr 2;387(10026):1405-1414. Epub 2015 Dec 21 doi: 10.1016/S0140-6736(15)01238-6. PMID: 26719230

Clinical prediction guides

CD70 and PD-L1 (CD274) co-expression predicts poor clinical outcomes in patients with pleural mesothelioma.
Inaguma S, Ueki A, Lasota J, Komura M, Sheema AN, Czapiewski P, Langfort R, Rys J, Szpor J, Waloszczyk P, Okoń K, Biernat W, Schrump DS, Hassan R, Miettinen M, Takahashi S
J Pathol Clin Res 2023 May;9(3):195-207. Epub 2023 Feb 8 doi: 10.1002/cjp2.310. PMID: 36754859Free PMC Article
What's Current and What's New in Mesothelioma?
Leal JL, Hoang W, Xue J, Dunne B, John T, Harden S
Clin Oncol (R Coll Radiol) 2022 Nov;34(11):771-780. Epub 2022 Sep 22 doi: 10.1016/j.clon.2022.08.029. PMID: 36155156
Nivolumab plus ipilimumab in malignant pleural mesothelioma.
Travert C, Tomasini P, Greillier L
Expert Rev Anticancer Ther 2022 Aug;22(8):815-822. Epub 2022 Jul 25 doi: 10.1080/14737140.2022.2102482. PMID: 35835722
Immune Checkpoint Inhibition for Unresectable Malignant Pleural Mesothelioma.
Cui W, Popat S
Drugs 2021 Jun;81(9):971-984. Epub 2021 Jun 9 doi: 10.1007/s40265-021-01506-0. PMID: 34106454
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Rivière F, Janicot H, Gervais R, Locher C, Milleron B, Tran Q, Lebitasy MP, Morin F, Creveuil C, Parienti JJ, Scherpereel A; French Cooperative Thoracic Intergroup (IFCT)
Lancet 2016 Apr 2;387(10026):1405-1414. Epub 2015 Dec 21 doi: 10.1016/S0140-6736(15)01238-6. PMID: 26719230

Recent systematic reviews

Meta-Analysis on the Combination of Chemotherapy With Programmed Death-Ligand 1 and Programmed Cell Death Protein 1 Blockade as First-Line Treatment for Unresectable Pleural Mesothelioma.
Tagliamento M, Di Maio M, Remon J, Bironzo P, Genova C, Facchinetti F, Aldea M, Le Péchoux C, Novello S, Barlesi F, Besse B, Planchard D
J Thorac Oncol 2024 Jan;19(1):166-172. Epub 2023 Aug 9 doi: 10.1016/j.jtho.2023.08.004. PMID: 37567387

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...